Drug Name: | Dicloxacillin (3116-76-5) |
---|---|
PubChem ID: | 18381 |
SMILES: | CC1=C(C(=NO1)C2=C(C=CC=C2Cl)Cl)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O |
InchiKey: | YFAGHNZHGGCZAX-JKIFEVAISA-N |
Therapeutic Category: | Anti-Bacterial Agents, Anti-Infective Agents |
Molecular Weight (dalton) | : | 470.334 |
LogP | : | 3.20212 |
Ring Count | : | 2 |
Hydrogen Bond Acceptor Count | : | 6 |
Hydrogen Bond Donor Count | : | 2 |
Total Polar Surface Area | : | 112.74 |
This panel provides information on interacting drugs and their ADRs along with references
Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
---|
This panel provides drug-protein interaction and their ADRs along with references
Toxicity | Interacting Protein | Mechanism | Reference |
---|---|---|---|
Infusion Phlebitis | Intercellular adhesion molecule 1 precursor (P05362) | Despite constitutive expression of ICAM-1 (34%) in HUVEC@ dicloxacillin or erythromycin significantly increased the number of cells with ICAM-1 expression by 37% and 30%@ respectively@which leads to pathogenesis of infusion phlebitis [ ADR Type 1 ] | Dicloxacillin and erythromycin at high concentrations increase ICAM-1 expression by endothelial cells: a possible factor in the pathogenesis of infusion phlebitis |
This panel provides drug-food interactions and their ADRs along with references
Food | Toxicity | Reference |
---|
This panel provides information on metabolites and their ADRs along with references
Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
---|
This panel provides information on drug category